The key to safer adhesive removal

DETACHOL: THE KEY
TO SUCCESSFUL
ADHESIVE REMOVAL
The key
• Completely removes adhesive residue
to safer
• Reduces the chance of skin tears and infections
adhesive
• Saves time and reduces patient pain and anxiety
• Is safe for all patient types includingremoval?
geriatric
and pediatric patients
POSITIVELY.
Available in
several
convenient
configurations
ORDERING INFORMATION
Description
Detachol Vials
Detachol Unit Dose
Detachol Dispenser Cap
Detachol Dispenser Cap
Unit
HRI #
Quick,
15mL Bottle with plug
painless,
2oz Bottle
4oz easy,
Bottle
and safe.
48 X 2/3 mL
0496-0513-48
0496-0513-15
0496-0513-06
0496-0513-04
Contact Eloquest Healthcare® toll free: 1.877.433.7626,
ext. 298 for product inquiries, ext. 234 for customer service
OR www.detachol.com
®
The care-ful move in adhesive removal
REFERENCES
1. Rippon M, White R, Davies P.
Wounds UK. 2007;3(4):76-86.
2. Berkowitz DM, Lee WS, Pazin
GJ, Yee RB, Ho M. Appl Microbiol.
1974;28(4):651-654. 3. Redelmeier
DA, Livesley NJ. J Gen Intern Med.
1999;14(6):373-375. 4. Lawton S,
Langoen A. Assessing and
managing vulnerable periwound
skin. World Wide Wounds. October
2009. Accessed October 3, 2012.
Available at: http://www.worldwide
wounds.com/2009/October/LawtonLangoen/vulnerable-skin-2.html.
5. Bryant RA. Types of skin damage
and differential diagnosis. In: Bryan
RA, Nix DP, eds. Acute and Chronic
Wounds: Current Management
Concepts. St. Louis, MO: Elsevier
Mosby; 2012: chap 5:83-107.
6. Coha T, Bryant RA, Nix DP. Skin
care needs of the pediatric and
neonatal patient. Part I: The
pediatric patient. In: Bryan RA, Nix
DP, eds. Acute and Chronic Wounds:
Current Management Concepts.
St. Louis MO: Elsevier Mosby;
2012:chap 36:485-502.
7. Pennsylvania Patient Safety
Authority, Patient Safety Advisory.
Skin tears: the clinical challenge.
Accessed October 3, 2012. Available
at: http://patientsafetyauthority.org/
ADVISORIES/AdvisoryLibrary/2006/
Sep3(3)/Pages/01b.aspx.
8. Rolstad BS, Bryant RA, Nix DP.
Topical management. In: Bryan RA,
Nix DP, eds. Acute and Chronic
Wounds: Current Management
Concepts. St. Louis, MO: Elsevier
Mosby; 2012: chap 18:289-306.
9. Fowler JF. Data on file. Eloquest
Healthcare, Inc; 2011.
Scan here to watch the
Detachol instructional
video or visit
www.detachol.com
to see for yourself
Our product portfolio includes:
• Mastisol® Liquid Adhesive
• Detachol® Adhesive Remover
• Microcyn® Rx Skin and Wound Cleanser
• LMX4® Topical Anesthetic
Detachol®, Mastisol®, and LXM4® are
registered trademarks of Ferndale IP, Inc.
Microcyn® is a registered trademark of Oculus
Innovative Sciences, Inc.
www.eloquesthealthcare.com
© 2012 Eloquest Healthcare®, Inc.
DE15 11/12
The key
to safer
adhesive
removal
• Quick
• Painless
• Easy
The key
to safer
adhesiv
remova
POSITIVE
Quick,
painless,
easy,
and safe.
The care-ful move in adhesive removal
ELO 9399 DET Sales Aid PD2.indd 1-2
12/5/12 11:39 AM
UNLOCK THE SOLUTION
TO HIDDEN THREATS
“Detachol…
has decreased
skin tears and
increased patient
satisfaction.”
Trauma resulting from adhesive tape and dressing removal can
Lori B
Pediatric CNS
Madison, WI
Additional skin threats
• Increase the size of wounds
• Delay healing1
• A
dhesive tape has long been recognized as a potential source of
nosocomial infections2,3
hen skin is exposed to moisture, the risk of bacterial
- W
colonization increases5
tripping on vulnerable periwound skin can lead to inflammatory skin
- S
damage, edema, soreness, and pain4,5
The key
Maximize comfort and ease of use
Minimize risk of infection
to safer
• Quickly, effortlessly, and completely
adhesive
removes adhesive and its residue
removal?
• Prevents skin tears that contribute to the
Use Detachol for safe and
painless adhesive removal
risk of local infection; won’t compromise
skin barrier
POSITIVELY.
• C
ompletely removes residue in which
bacteria can breed
Dressing changes are often painful 6
• Reduces patient pain and discomfort
• P
atient pain from skin trauma and tears from adhesive tape removal can
be avoided
Central line dressings
NPWT dressings
Catheter securement devices
Nasogastric tube securements
Peripheral IV dressings
Endotracheal tube securements
And many more!
Balance patient protection and
resource preservation
• U
se of a solvent to break the bond between adhesive and skin is
recommended as an approach to prevent injury5,7,8
By effectively removing it,
Detachol can help reduce
the risk of infection.
Diane P
RN, WOCN
Aurora, CO
• Exacerbate wound pain
• Stripping cells from the epidermis can cause skin tears 4
Detachol helps remove
leftover adhesive residue,
which can harbor
microorganisms.
DETACHOL OPENS
THE WAY TO OPTIMAL
PATIENT COMFORT
AND OUTCOMES
“{Detachol}…
left no residue
on the skin, and
allowed for
much more time
efficient care…”
• C
an reduce physical, emotional, and
monetary costs of adhesive removalrelated, hospital-acquired skin infection
Quick,
painless, •
easy,
•
and safe.
Is pain-free for pediatric patients, geriatric
patients, and sensitive skin types
Does not irritate or dry the skin9
• Q
uickly and easily removes adhesive
to save healthcare professional time
• No harsh alcohol or acetone
• W
ill not degrade sterile gloves like
alcohol-based adhesive removers
The care-ful move in adhesive removal
ELO 9399 DET Sales Aid PD2.indd 3-4
12/5/12 11:40 AM
DETACHOL: THE KEY
TO SUCCESSFUL
ADHESIVE REMOVAL
The key
• Completely removes adhesive residue
to safer
• Reduces the chance of skin tears and infections
adhesive
• Saves time and reduces patient pain and anxiety
• Is safe for all patient types includingremoval?
geriatric
and pediatric patients
POSITIVELY.
Available in
several
convenient
configurations
ORDERING INFORMATION
Description
Detachol Vials
Detachol Unit Dose
Detachol Dispenser Cap
Detachol Dispenser Cap
Unit
HRI #
Quick,
15mL Bottle with plug
painless,
2oz Bottle
4oz easy,
Bottle
and safe.
48 X 2/3 mL
0496-0513-48
0496-0513-15
0496-0513-06
0496-0513-04
Contact Eloquest Healthcare® toll free: 1.877.433.7626,
ext. 298 for product inquiries, ext. 234 for customer service
OR www.detachol.com
®
The care-ful move in adhesive removal
REFERENCES
1. Rippon M, White R, Davies P.
Wounds UK. 2007;3(4):76-86.
2. Berkowitz DM, Lee WS, Pazin
GJ, Yee RB, Ho M. Appl Microbiol.
1974;28(4):651-654. 3. Redelmeier
DA, Livesley NJ. J Gen Intern Med.
1999;14(6):373-375. 4. Lawton S,
Langoen A. Assessing and
managing vulnerable periwound
skin. World Wide Wounds. October
2009. Accessed October 3, 2012.
Available at: http://www.worldwide
wounds.com/2009/October/LawtonLangoen/vulnerable-skin-2.html.
5. Bryant RA. Types of skin damage
and differential diagnosis. In: Bryan
RA, Nix DP, eds. Acute and Chronic
Wounds: Current Management
Concepts. St. Louis, MO: Elsevier
Mosby; 2012: chap 5:83-107.
6. Coha T, Bryant RA, Nix DP. Skin
care needs of the pediatric and
neonatal patient. Part I: The
pediatric patient. In: Bryan RA, Nix
DP, eds. Acute and Chronic Wounds:
Current Management Concepts.
St. Louis MO: Elsevier Mosby;
2012:chap 36:485-502.
7. Pennsylvania Patient Safety
Authority, Patient Safety Advisory.
Skin tears: the clinical challenge.
Accessed October 3, 2012. Available
at: http://patientsafetyauthority.org/
ADVISORIES/AdvisoryLibrary/2006/
Sep3(3)/Pages/01b.aspx.
8. Rolstad BS, Bryant RA, Nix DP.
Topical management. In: Bryan RA,
Nix DP, eds. Acute and Chronic
Wounds: Current Management
Concepts. St. Louis, MO: Elsevier
Mosby; 2012: chap 18:289-306.
9. Fowler JF. Data on file. Eloquest
Healthcare, Inc; 2011.
Scan here to watch the
Detachol instructional
video or visit
www.detachol.com
to see for yourself
Our product portfolio includes:
• Mastisol® Liquid Adhesive
• Detachol® Adhesive Remover
• Microcyn® Rx Skin and Wound Cleanser
• LMX4® Topical Anesthetic
Detachol®, Mastisol®, and LXM4® are
registered trademarks of Ferndale IP, Inc.
Microcyn® is a registered trademark of Oculus
Innovative Sciences, Inc.
www.eloquesthealthcare.com
© 2012 Eloquest Healthcare®, Inc.
DE15 11/12
The key
to safer
adhesive
removal
• Quick
• Painless
• Easy
The key
to safer
adhesiv
remova
POSITIVE
Quick,
painless,
easy,
and safe.
The care-ful move in adhesive removal
ELO 9399 DET Sales Aid PD2.indd 1-2
12/5/12 11:39 AM
NOTHING SECURES
LIKE MASTISOL
®
“Locks down” catheter dressings to help adhere to CDC guidelines
ENSURE COMPLIANCE
WITH CDC GUIDELINES
Protect against the risk of infection
Subclavian central line
catheter dressing
CDC Guidelines for the Prevention of Intravascular Catheter-Related
Infections recommend:
• R
eplacement of catheter site dressing if damp, loosened, or visibly soiled
(Category I B )1
• R
eplacement of dressings on short-term central venous catheter (CVC)
sites at least every 7 days (Category I B )1
CDC Guidelines for the Prevention of Catheter-Associated
Urinary Tract Infections recommend:
• P
roperly secured indwelling catheters after insertion to prevent movement
and urethral traction (Category I B )2
DATA POINT
In a clinical study,
6 times the number
of patient dressings
secured with Mastisol
remained intact
compared to dressings
secured with benzoin.4
Assure adherence
• Mastisol is a nonwater soluble adhesive
nsures that dressings will remain intact if the patient
- E
is diaphoretic or if the dressings are placed in moist,
contaminant prone areas
• More than 8 million applications every year3
• Adhesion is superior to tincture of benzoin4
Foley catheter
securement device
Improve the level of security
Reduce the risk of infection
• R
ecent data suggests that dressing disruptions are a major risk factor
for catheter-related infections5
• In a study of catheter-related bloodstream infections:
60% of infections were attributed to skin flora or other contamination
coming in contact with the catheter insertion point6
• M
astisol minimizes infection risk by helping to keep the system closed
and the dressing intact for the recommended dressing stay time
Enhance tape/dressing performance
• In a study designed to evaluate the effects of different techniques
used to secure intravenous catheters: Pretreatment of skin with Mastisol
enhanced the adhesive performance of all tapes tested,* better than
benzoin or no treatment at all7
• M
astisol can also enhance the adhesive performance of a variety of
occlusive dressings and devices
SECURE BENEFITS
FOR PATIENTS AND
CLINICIANS ALIKE
DATA POINT
A study showed that
contact dermatitis
developed in 38%
(57/150) of benzointreated patients
compared with 0.7%
(1/150) of Mastisoltreated patients.4
Range of sizes
and sterile
unit-of-use vials
provide:
• Efficiency
• Value
• Standardization
• Mastisol can improve patient safety
inimizes the risk of infection by creating a lasting occlusive dressing
- M
barrier, particularly around CVC sites
astisol is compatible with CHG8
- M
Peripheral IV
catheter dressing
educes the likelihood of dressing displacement and device dislodgement
- R
educed risk of adverse reactions (lower incidence of postoperative
- R
contact dermatitis and skin discoloration than tincture of benzoin)4
- Is latex free to alleviate potential allergic reactions
• Mastisol assures convenience and versatility for
healthcare professionals
ong-lasting adhesion saves time and cost of
- L
multiple dressing replacements or device
dislodgements
ersatility across a range of procedures
- V
and applications
*Maximum force (Newtons)
to dislodge IV catheters using
Transpore (plastic), Curity
(cloth), and Leukopor (silk)
tape alone, and with Mastisol
and benzoin skin pretreatment.
MASTISOL SUPPORTS YOUR
INITIATIVES TO MEET
CDC RECOMMENDATIONS
CDC GUIDELINES
For prevention of intravascular catheter-related infections (Category IB)1
For prevention of catheter-associated urinary tract infections (Category IB)2
Procedures &
Applications
• Central line dressings
• Foley catheter securement
• Mastisol improves patient safety by
• Peripheral IV dressings
- Minimizing the risk of infection by reinforcing the dressing barrier
- Reducing the chance of device dislodgement and dressing displacement
- Helping to secure dressings even in moist areas
• ET tube securement
• NG tube securement
• Wound closure strips
• V.A.C.® Therapy Dressings
• Mastisol assures convenience and versatility for healthcare professionals
ong-lasting adhesion saves time and cost of multiple
- L
dressing replacements or device dislodgements
Additional beneficial
products include: Detachol®
Adhesive Remover and L.M.X.4®
Topical Anesthetic Cream
- Versatility across a range of procedures
and applications
- Range of sizes including sterile unit-of-use vials
ORDERING INFORMATION
DESCRIPTION
UNIT
HRI#
Mastisol Vials
48 X 2/3mL
0496-0523-48
Mastisol Unit Dose
15mL bottle with plug
0496-0523-15
Mastisol Spray
15mL bottle with spray
0496-0523-16
Mastisol Dispenser Cap
2oz bottle
0496-0523-06
For more information, please contact your sales
consultant or Eloquest Healthcare® toll free:
1-877-433-7626, or on the web: www.mastisol.com
References: 1. Guidelines for the
prevention of intravascular catheterrelated infections. 2011. Centers
for Disease Control website. http://
www.cdc.gov/hicpac/pdf/guidelines/
bsi-guidelines-2011.pdf. Accessed
January 29, 2013. 2. Guidelines for
the prevention of catheter-associated
urinary tract infections. 2009. Centers
for Disease Control website. http://
www.cdc.gov/hicpac/pdf/CAUTI/
CAUTIguideline2009final.pdf.
Accessed January 29, 2013. 3. GHX
Market Data, Liquid Adhesives Class
10-036, 2012. 4. Lesesne CB. The
postoperative use of wound adhesives:
gum mastic versus benzoin, USP. J
Dermatol Surg Onc.1992;18(11):990.
5. Timsit J, et al. Dressing disruption
is a major risk factor for catheterrelated infections. Crit Care Med.
2012;40(6):1707-1714. 6. Safdar
N, Maki DG. The pathogenesis of
catheter-related bloodstream infections
with noncuffed short-term central
venous catheters. Int Care Med. 2004;
30:62-67. 7. Patel N. The influence
of tape type and of skin preparation
on the force required to dislodge
angiocatheters. Can J Anaesth.
1994;41:8:738-741. 8. Data on file.
Mastisol, Eloquest Healthcare,
Detachol, Microcyn Rx Solution, and
L.M.X.4 are registered trademarks of
Ferndale IP, Inc.
V.A.C.® is a registered trademark of KCI
Licensing, Inc.
®
Mastisol is an essential product in the Eloquest Healthcare® portfolio.
© 2013 Eloquest Healthcare®, Inc.
MA40 3/13